

Natto: Christopher von Schirach-Szmigiel elected as member of the board of directors

Christopher von Schirach-Szmigiel was elected as member of the Board of Directors in NattoPharma ASA for a period of two years at the General Assembly 25th June 2015. Frode Marc Bohan remains Chairman of the Board as his position was not up for election. Katrazyna Maresz was elected as Board member for another two-year period.

Christopher von Schirach-Szmigiel is born in Poland and settled in Stockholm. He speaks several languages and is worldwide recognised for his scientific achievements, business skills and abilities to "think out of the box" in strategic positioning of global businesses. He is educated within finance and management and has held positions as visiting professor in finance, management and strategic management and leadership among other places at New York University, Stockholm School of Economics, Norges Handelshøyskole, Bergen, Norway and the Pennsylvania State University.

Christopher von Schirach-Szmigiel was Board Director in Uniliver Nordic, Stora Data, Ericsson Group, Audi-Volkswagen Scandinavia and Porsche. He has also served as Board director at Universities in Sweden, USA and Poland and has been expert and advisor for the Swedish government in shipping and shipbuilding.

Christopher von Schirach-Szmigiel has the last five years focused his activities on the Board of Directors in companies with commercial opportunities where he believes his participation can make a difference – through increasing the company growth rate. Christopher von Schirach-Szmigiel has been in contact with key people within NattoPharma ASA for the last two years, and has expressed an interest in the company. Through his new position as member of the Board of Directors he will inspire, guide and utilize his global business network as a for NattoPharma ASA ambassador.

"The election of Christopher von Schirach-Szmigiel as member of the Board of Directors in NattoPharma ASA is a part of the plan to move NattoPharma from an "entrepreneurial start-up company" within the dietary supplement business segment to a visible player within global biotechnology, neutraceutical and the pharmaceutical field – growing our current business and systematically developing us towards a recognized pharmaceutical company" says Frode M. Bohan, Chairman of the Board in NattoPharma ASA.

"Christopher von Schirach-Szmigiel has the strategic vision to move companies to a higher level of knowledge – and states that learning faster than your competitors is the only sustainable competitive advantage. I am looking forward to working with him and together secure growth and create shareholder values", says Hogne Vik, CEO in NattoPharma.

#

About MenaQ7®

MenaQ7[®] provides natural vitamin K2 as a manufactured fermentation extract. This process generates a highly pure and bio-available form of vitamin K2, menaquinone-7(MK-7). MenaQ7 is the purest and best documented natural vitamin K2 with guaranteed actives and stability, clinical substantiation and several granted patents on cardiovascular health.

About NattoPharma

As a biotechnology-based nutraceutical company, NattoPharma is the worldwide innovator and leader of Vitamin K2 menaquinone-7. Its brand MenaQ7[®] is supported by a global IPR portfolio and research substantiating clear efficacy for bone and cardiovascular health. NattoPharma has since 2007 been in a research and development collaboration with the University in Maastricht, The Netherlands, working to substantiate the health benefits of vitamin K2.

For more information, please contact:

Hogne Vik,

CEO (+47-97535326

Hogne.vik@nattopharma.com